Research Saves Lives

Because of medical research, improvements have been made to early detection and treatment of breast cancer that have led to a 40% decrease in mortality in the U.S. over the past 30 years. There are more than 3.8 million breast cancer survivors in the U.S. Despite this tremendous progress, more than 42,000 women and men still die from breast cancer every year in the U.S. We can do better. Which is why in 2016, Komen set a Bold Goal to reduce the current number of breast cancer deaths in the U.S. by 50 percent by 2026.

We listened to our patient advocates and worked with our scientific advisors to set research priorities to help us achieve this goal: conquering metastatic breast cancer (MBC), eliminating disparities in outcomes and putting Big Data to work for breast cancer patients.

Visit the Fast Facts series to learn more about our research investment on a particular topic.

Our research investments are guided by more than 50 leading scientists and advocates, including our Scientific Advisory Board and Komen Scholars.

We fund the brightest minds and the best breast cancer research — research that has the potential to help us achieve our Bold Goal. Our research program is patient-focused, with patient advocates involved in all steps of the research process.

As a global leader in the fight against breast cancer, we have funded research in 47 states and the District of Columbia, and 24 different countries. Our commitment to the most promising, innovative and meaningful research will never waver.

Support Mission Programs
Learn how you can donate to a specific project

Our Research Investment
1982—2019

More than $1 billion in more than 2700 research grants and more than 500 clinical trials

What are Komen-funded researchers doing right now?

- Developing and testing new and improved treatments for metastatic breast cancer starting with an understanding of the biology of breast cancer and how it spreads.
- Developing better treatments for aggressive forms of breast cancer and those that tend to become resistant to treatment and become metastatic.
- Identifying the factors that contribute to breast cancer disparities and developing tools and methods to improve access and utilization of quality breast cancer care among vulnerable populations.
- Using Big Data and transformative technology such as artificial intelligence to fuel scientific discoveries and accelerate the delivery of equitable, patient-focused care.

What’s in Komen’s Research Pipeline

<table>
<thead>
<tr>
<th>More than 450</th>
<th>More than 120</th>
<th>More than 100</th>
</tr>
</thead>
<tbody>
<tr>
<td>New research products (drugs, biomarkers, devices, etc.) supporting Komen’s Bold Goal</td>
<td>New therapies, more than half of which are focused on metastatic breast cancer</td>
<td>New strategies to reduce breast cancer disparities like better healthcare delivery methods</td>
</tr>
</tbody>
</table>

Learn More About Breast Cancer
Learn More About Komen-funded Research
Get Involved & Support Komen Research

©2019 Susan G. Komen® The Running Ribbon is a registered trademark of Susan G. Komen. September 2019